



International Distributor of
Medicinal Cannabis

ASX ANNOUNCEMENT

ASX CODE: HHI

16 November 2022

HHI completes CanPharma sale and Board changes

Further to the ASX announcement on 1 November 2022, **Health House International Ltd (ASX:HHI) (Health House or the Company)** is pleased to announce completion of the sale of CanPharma GmbH (**CanPharma**) to Ms Sabine Jacker (**Transaction**) following the satisfaction of all conditions precedent.

The sale of CanPharma removes actual and contingent liabilities of approx. €2,887,000 (AUD\$4,456,000) from the Health House group's balance sheet.

Health House further advises that Dr Henrik Sprengel has resigned effective immediately from the position of executive director. The Company wishes to thank Dr Sprengel for his contribution as a director since his appointment as part of the CanPharma acquisition in August 2021.

The sale of CanPharma will have no impact on the arrangement agreed between Health House and Creso Pharma Limited (**Creso**), pursuant to which Creso proposes to acquire 100% of Health House via a scheme of arrangement as announced on 29 July 2022 (**Scheme**). The Company expects to be in a position to update the market in respect of the Scheme by the end of November 2022.

This announcement has been approved and authorised for release by the board of Health House International Limited.

David Wheeler

Chairman

About Health House

The Health House International Group is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

For more information, please visit www.healthhouse.com.au

Address

Level 3
101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au

ACN 149 197 651

For further information please contact

Company

David Wheeler
Chairman
david@pathwayscorporate.com.au

Tim Slate

Company Secretary
tim.slate@healthhouse.com.au

Investors

Jason Peterson
Corporate Advisor
jason.peterson@cpscapital.com.au